HomeCompareAGE vs SBUX

AGE vs SBUX: Dividend Comparison 2026

AGE yields 18.02% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $102.4K in total portfolio value· pulled ahead in Year 8
10 years
AGE
AGE
● Live price
18.02%
Share price
$11.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.6K
Annual income
$5,421.64
Full AGE calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — AGE vs SBUX

📍 SBUX pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGESBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGE + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGE pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGE
Annual income on $10K today (after 15% tax)
$1,531.53/yr
After 10yr DRIP, annual income (after tax)
$4,608.39/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $55,857.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGE + SBUX for your $10,000?

AGE: 50%SBUX: 50%
100% SBUX50/50100% AGE
Portfolio after 10yr
$115.8K
Annual income
$38,279.05/yr
Blended yield
33.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

AGE
No analyst data
Altman Z
-20.5
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGE buys
0
SBUX buys
0
No recent congressional trades found for AGE or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGESBUX
Forward yield18.02%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$64.6K$167.0K
Annual income after 10y$5,421.64$71,136.45
Total dividends collected$34.8K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: AGE vs SBUX ($10,000, DRIP)

YearAGE PortfolioAGE Income/yrSBUX PortfolioSBUX Income/yrGap
1$12,502$1,801.80$11,121$420.68+$1.4KAGE
2$15,482$2,105.21$12,548$648.40+$2.9KAGE
3$19,002$2,436.52$14,440$1,013.98+$4.6KAGE
4$23,127$2,794.89$17,068$1,617.30+$6.1KAGE
5$27,925$3,179.07$20,912$2,649.52+$7.0KAGE
6$33,468$3,587.47$26,875$4,499.29+$6.6KAGE
7$39,829$4,018.19$36,771$8,014.12+$3.1KAGE
8← crossover$47,086$4,469.06$54,542$15,197.11$7.5KSBUX
9$55,319$4,937.71$89,602$31,242.49$34.3KSBUX
10$64,613$5,421.64$167,011$71,136.45$102.4KSBUX

AGE vs SBUX: Complete Analysis 2026

AGEStock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Full AGE Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this AGE vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGE vs SCHDAGE vs JEPIAGE vs OAGE vs KOAGE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.